Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate

Journal of Hematology & Oncology

Shinji Nakao³  Hidesaku Asakura¹  Yukihiro Shimizu²  Masahisa Arahata² 

[1] Department of Internal Medicine (III), Kanazawa University Graduate School of Medical Science, Kanazawa, Japan;Department of Internal Medicine, Nanto Municipal Hospital, 938 Inami, Nanto 932-0211, Toyama, Japan;Department of Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

关键词: Elderly;    Refractory;    Inv(16)(p13.1q22);    Acute myeloid leukemia;    Cytarabine ocfosfate hydrate;   

Others  :  1133470
DOI  :  10.1186/s13045-014-0100-6

 received in 2014-12-27, accepted in 2014-12-27,  发布年份 2015

【 摘 要 】

The prognosis of relapsed acute myeloid leukemia (AML) in elderly patients is dismal, even if the AML exhibits a good prognostic karyotype, such as inv(16)(p13.1q22). We present a 72-year-old female with AML with inv(16)(p13.1q22) who suffered five episodes of relapse with temporary complete remission. Maintenance chemotherapy with oral cytarabine ocfosfate hydrate eventually produced persistent molecular complete remission of her AML that had not been induced by conventional regimens including intensive chemotherapy and low dose cytarabine therapy. The high level of tolerability to oral cytarabine ocfosfate hydrate may offer elderly patients with this type of AML a good chance for a cure.

【 授权许可】

   
2015 Arahata et al.; licensee Biomed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, et al.: Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003, 102:462-469.
• [2]Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al.: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
• [3]Vey N, Coso D, Bardou VJ, Stoppa AM, Braud AC, Bouabdallah R, et al.: The benefit of induction chemotherapy in patients age > or = 75 years. Cancer 2004, 101:325-331.
• [4]Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, et al.: Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: A collaborative study of the French CBF-AML Intergroup. J Clin Oncol 2009, 27:4747-4753.
• [5]Brandwein JM, Geddes M, Kassis J, Kew AK, Leber B, Nevill T, et al.: Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus. Am J Blood Res 2013, 3:141-164.
• [6]O’Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, et al.: Acute Myeloid Leukemia. J Natl Compr Canc Netw 2012, 10:984-1021.
• [7]Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al.: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
• [8]Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C, et al.: Guidelines on the management of acute myeloid leukemia in adults. Br J Haematol 2006, 135:450-474.
• [9]Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al.: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114–-1124.
• [10]Ferrara F, Palmieri S, Mele G: Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004, 89:998-1008.
• [11]Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al.: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23:5705-5717.
• [12]Wakita A, Ohtake S, Takada S, Yamasaki F, Komatsu H, Miyazaki Y, et al.: Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. Int J Hematol 2012, 96:84-93.
• [13]Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, et al.: Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 1994, 54:109-113.
• [14]Okumura H, Yoshida T, Takamatsu H, Katoh T, Murashima M, Watanabe A, et al.: Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor. Int J Hematol 1997, 65:263-268.
• [15]Horikoshi A, Takei K, Hosokawa Y, Sawada S: The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. Int J Hematol 2008, 87:118-125.